Drug Delivery Partnering Terms and Agreements

 Published On: Feb, 2015 |    No of Pages: 2879 |  Published By: CurrentPartnering | Format: PDF
Download Free Sample

The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The drug delivery technology includes the following sub-technology areas:

Drug Delivery

Bioavailability
Implanatable
Oral delivery
Rapid release
Delayed release
Parenteral
Infusion
Injectable
Pro-drug
Targeted
Topical
Transdermal
Buccal
Inhaled
Nasal
Ocular
Rectal
Sublingual
Urogenital

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking.

Chapter 3 provides a review of the leading drug delivery deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by drug delivery partnering company A-Z, deal type definitions and drug delivery partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.

Drug Delivery Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to drug delivery trends and structure of deals entered into by leading companies worldwide.

Drug Delivery Partnering Terms and Agreements includes:

-Trends in drug delivery dealmaking in the biopharma industry since 2009
-Analysis of drug delivery deal structure and contract documents
-Access to headline, upfront, milestone and royalty data
-Case studies of real-life drug delivery deals
-Access to over 2,000 drug delivery deals announced
-The leading drug delivery deals by value since 2009
-Most active drug delivery dealmakers since 2009
-The leading drug delivery partnering resources

In Drug Delivery Partnering Terms and Agreements, the available contracts are listed by:

-Company A-Z
-Headline value
-Stage of development at signing
-Deal component type
-Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Drug Delivery Partnering Terms and Agreements provides the reader with the following key benefits:

-In-depth understanding of drug delivery deal trends since 2009
-Access to headline, upfront, milestone and royalty data
-Analysis of the structure of drug delivery agreements with numerous real life case studies
-Comprehensive access to over 2,000 actual drug delivery deals entered into by the world’s biopharma companies, together with contract documents where available
-Detailed access to actual drug delivery contracts enter into by the leading fifty big pharma and big biotech companies
-Identify leading drug delivery deals by value since 2009
-Identify the most active drug delivery dealmakers since 2009
-Insight into the terms included in a drug delivery agreement, together with real world clause examples
-Understand the key deal terms companies have agreed in previous deals
-Undertake due diligence to assess suitability of your proposed deal terms for partner companies 

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in drug delivery dealmaking

2.1. Introduction
2.2. Drug delivery partnering over the years
2.3. Big pharma drug delivery dealmaking activity
2.4. Big biotech drug delivery dealmaking activity
2.5. Most active drug delivery dealmakers
2.6 Drug delivery partnering by deal type
2.7. Drug delivery partnering by disease type
2.8. Partnering by drug delivery technology type
2.9. Average deal terms for drug delivery partnering
2.9.1 Drug delivery headline values
2.9.2 Drug delivery upfront payments
2.9.3 Drug delivery milestone payments
2.9.4 Drug delivery royalty rates
2.10. The anatomy of drug delivery partnering
2.11. Drug delivery or specialty pharma?
2.11.1. Is specialty pharma the only way for drug delivery?
2.11.2. Best practice for optimizing drug delivery program development
2.11.3. The anatomy of a drug delivery deal
2.11.3. a. Case study 1: Uluru – Oradisc – Oct 2012
2.11.3.b. Case study 2: Ohio State University – Microlin Bio – Sep 2013
2.11.3.c. Case study 3: Endo Pharmaceuticals – BioDelivery Sciences – Jan 2012

Chapter 3 – Leading drug delivery deals
3.1. Introduction
3.2. Top drug delivery deals by value

Chapter 4 – Big pharma drug delivery deals
4.1. Introduction
4.2. How to use big pharma drug delivery partnering deals
4.3. Big pharma drug delivery partnering company profiles

Chapter 5 – Big biotech drug delivery deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech drug delivery partnering company profiles

Chapter 6 – Drug delivery partnering contracts directory

6.1. Introduction
6.2. Company A-Z
6.3. By deal type
6.4. By stage of development
6.5. By therapy area

Chapter 7 – Drug delivery dealmaking by technology type

7.1. Introduction
7.2. Deals by drug delivery type
Drug delivery
Bioavailability
Implantable
Oral delivery
Delayed release
Rapid release
Parenteral
Infusion
Injectable
Pro-drug
Targeted
Topical
Transdermal
Transmucosal
Buccal
Inhaled
Nasal
Ocular
Rectal
Sublingual
Urogenital
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering

See accompanying volume for:
Appendices
Introduction
Appendix 1 – Directory of drug delivery deals by company A-Z 2009-2014
Appendix 2 – Directory of drug delivery deals by stage of development 2009-2014
Appendix 3 – Directory of drug delivery deals by deal type 2009-2014
Appendix 4 – Directory of drug delivery deals by therapy area 2009-2014
Appendix 5 – Drug delivery partnering resource center
Online drug delivery partnering
Drug delivery partnering events
Further reading on drug delivery dealmaking

Table of Figures

Figure 1: Drug delivery partnering since 2009
Figure 2: Big pharma – top 50 – drug delivery deals 2009 to 2014
Figure 3: Big pharma drug delivery deal frequency – 2009 to 2014
Figure 4: Big biotech – top 50 – drug delivery deals 2009 to 2014
Figure 5: Big biotech drug delivery deal frequency – 2009 to 2014
Figure 6: Active drug delivery dealmaking activity– 2009 to 2014
Figure 7: Drug delivery partnering by deal type since 2009
Figure 8: Drug delivery partnering by disease type since 2009
Figure 9: Drug delivery partnering by technology type since 2009
Figure 10: Drug delivery deals with a headline value by year- 2014
Figure 11: Drug delivery deals with a headline value by year- 2013
Figure 12: Drug delivery deals with a headline value by year- 2012
Figure 13: Drug delivery deals with a headline value by year- 2011
Figure 14: Drug delivery deals with a headline value by year- 2010
Figure 15: Drug delivery deals with a headline value by year- 2009
Figure 16: Summary median headline value by year, 2009-2014
Figure 17: Drug delivery deals with an upfront value by year- 2014
Figure 18: Drug delivery deals with an upfront value by year- 2013
Figure 19: Drug delivery deals with an upfront value by year- 2012
Figure 20: Drug delivery deals with an upfront value by year- 2011
Figure 21: Drug delivery deals with an upfront value by year- 2010
Figure 22: Drug delivery deals with an upfront value by year- 2009
Figure 23: Summary median upfront value by year, 2009-2014
Figure 24: Drug delivery deals with a milestone value by year- 2014
Figure 25: Drug delivery deals with a milestone value by year- 2013
Figure 26: Drug delivery deals with a milestone value by year- 2012
Figure 27: Drug delivery deals with a milestone value by year- 2011
Figure 28: Drug delivery deals with a milestone value by year- 2010
Figure 29: Drug delivery deals with a milestone value by year- 2009
Figure 30: Drug delivery deals with a royalty rate value by year- 2014
Figure 31: Drug delivery deals with a royalty rate value by year- 2013
Figure 32: Drug delivery deals with a royalty rate value by year- 2012
Figure 33: Drug delivery deals with a royalty rate value by year- 2011
Figure 34: Drug delivery deals with a royalty rate value by year- 2010
Figure 35: Drug delivery deals with a royalty rate value by year- 2009
Figure 36: Summary median royalty rate by year, 2009-2014
Figure 37: Components of the typical drug delivery deal structure
Figure 38: Best practice for drug delivery program development
Figure 39: Top drug delivery deals by value since 2009


If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.